Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 1382 • ACR Convergence 2021
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Murray Baron² and Marie Hudson³, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Jewish General Hospital, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…
Abstract Number: 0541 • ACR Convergence 2021
N-formyl Methionine Peptide-mediated Neutrophil Activation in Systemic Sclerosis
Runa Kuley¹, Ryan Stultz², Bhargavi Duvvuri², Roger Hesselstrand³, J Lee Nelson⁴ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease, and its etiology is unknown. Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs)…
Abstract Number: 1383 • ACR Convergence 2021
Prediction of Digital Ulcers in Patients with Systemic Sclerosis Based on the Use of Platelet Inhibitors and Other Parameters – A EUSTAR Study on Derivation and Validation of a Clinical Prediction Model
Alexandru Garaiman¹, Klaus Steigmiller², Catherine Gebhard³, Marco Matucci-Cerinic⁴, Jorg Henes⁵, Jeska de Vries-Bouwstra⁶, Vanessa Smith⁷, Andrea Doria⁸, Yannick Allanore⁹, Lorenzo Dagna¹⁰, Branimir Anic¹¹, Carlomaurizio Montecucco¹², Otylia Kowal-Bielecka¹³, Mickael Martin¹⁴, Yoshiya Tanaka¹⁵, Anna-Maria Hoffmann-Vold¹⁶, Ulrike Held², Oliver Distler¹⁷ and Mike Oliver Becker¹⁸, ¹University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zurich, Zurich, Switzerland, ³Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Florence, Florence, Italy, ⁵University Hospital Tuebingen, Tuebingen, Germany, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁸University of Padova, Padova, Italy, ⁹Université de Paris, Paris, France, ¹⁰10Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milano, Italy, ¹¹Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia, ¹²Department of Rheumatology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, ¹³Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ¹⁴Internal Medicine, Poitiers University Hospital, Poitiers, France, ¹⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁶Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Digital ulcers (DUs) affect half of the patients with systemic sclerosis (SSc) and can be complicated by gangrene and amputation. Platelets are known to…
Abstract Number: 0544 • ACR Convergence 2021
Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis
Eliza Pei-Suen Tsou, M.Asif Amin, Phillip Campbell, Mikel Gurrea-Rubio, Morgan Omara, Ellen Model, Pamela Palisoc, Mustafa Ali, Sirapa Vichaikul, Jonatan Hervoso, Jeffrey Ruth, Dinesh Khanna and David Fox, University of Michigan, Ann Arbor, MI
Background/Purpose: Aminopeptidase N, also known as CD13, is a Zn2+-dependent membrane bound ectopeptidase widely expressed in mammalian cells including rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS),…
Abstract Number: 1389 • ACR Convergence 2021
Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases
Anna-Maria Hoffmann-Vold¹, Helena Andersson², Silje Reiseter², Håvard Fretheim², Imon Barua¹, Torhild Garen³, Øyvind Midtvedt¹, Ragnar Gunnarsson², Michael Durheim², Trond Mogens AAløkken² and Øyvind Molberg¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Oslo, Nepal
Background/Purpose: Based on the argument that symptoms-define-disease, physicians commonly apply the terms pre-clinical or sub-clinical disease to describe patients with disease-related findings, but no accompanying…
Abstract Number: 0545 • ACR Convergence 2021
SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells
Ellen Model, Morgan Omara, Pamela Palisoc, Dinesh Khanna and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI
Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…
Abstract Number: 1390 • ACR Convergence 2021
A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis
Alicia Hinze¹, Shreyasee Amin¹, Ashima Makol¹, Robert Vassallo¹, Cynthia Crowson² and Brian Bartholmai¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…
Abstract Number: 0546 • ACR Convergence 2021
Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Kristina Clark¹, Eszter Csomor², Corrado Campochiaro³, Adam Taylor⁴, Yee Voan Teo², Katherine Nevin², Mary Morse², Voon Ong⁵, Emma Derrett-Smith⁶, Nicolas Wisniacki², Shaun Flint² and Christopher Denton⁷, ¹University College London, London, United Kingdom, ²GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ³Royal Free Hospital London, London, United Kingdom, ⁴GlaxoSmithKline, London, United Kingdom, ⁵University College London Medical School Royal Free Campus, London, United Kingdom, ⁶University College London Division of Medicine, London, United Kingdom, ⁷University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
Abstract Number: 1437 • ACR Convergence 2021
Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis
Nancy Wareing¹, Brian Skaug², Minghua Wu³, Scott Collum¹, Cory Wilson¹, Lucy Revercomb⁴, Marka Lyons⁵, Weizhen Bi⁶, Tingting Mills¹, Julio Charles⁵, Shervin Assassi¹ and Harry Karmouty-Quintana¹, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²University of Texas McGovern Medical School Houston, Houston, TX, ³University of Texas Health Science Center at Houston, Houston, TX, ⁴Rice University, Houston, TX, ⁵Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, ⁶McGovern Medical School at UTHealth, Houston, TX
Background/Purpose: Early loss of skin-associated adipose tissue and concomitant replacement by extracellular matrix is a hallmark of systemic sclerosis (SSc). However, the contribution of adipose…
Abstract Number: 0548 • ACR Convergence 2021
Rapamycin Blocks the Profibrotic Effects of Fli1 Downregulation in Scleroderma Myeloid Cells
Fatima El-adili, Grace Marden, Maria Trojanowska and Andreea Bujor, Boston University School of Medicine, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune fibrotic disease with unclear pathogenesis and no effective therapies. Increased proportion of CD163-positive, profibrotic macrophages has been described…
Abstract Number: 1836 • ACR Convergence 2021
Outcomes Linked to Eligibility for Stem Cell Transplantation Trials in Diffuse Cutaneous Systemic Sclerosis
Julia Spierings¹, Svetlana Nihtyanova², Emma Derrett-Smith³, Kristina Clark², Jacob van Laar⁴, Voon Ong⁵ and Christopher Denton⁶, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²University College London, Royal Free Campus, London, United Kingdom, ³University College London Division of Medicine, London, United Kingdom, ⁴University Medical Centre Utrecht, Utrecht, Netherlands, ⁵University College London Medical School Royal Free Campus, London, United Kingdom, ⁶University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Autologous haematopoietic stem cell transplantation (SCT) has emerged as an effective treatment for patients with severe diffuse systemic sclerosis (dcSSc) based upon the results…
Abstract Number: 0552 • ACR Convergence 2021
Long Non-coding RNA H19X as a Regulator of Endothelial Adhesion Molecules in Systemic Sclerosis
Francesca Tirelli¹, Elena Pachera¹, Robert Lafyatis², Menqi Huang³, Francesco Zulian⁴, Gabriela Kania¹ and Oliver Distler⁵, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Rheumatology Unit, Department of Woman and Child Health - University of Padova, Padova, Italy, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland
Background/Purpose: Long non-coding RNAs (lncRNAs) are non-coding transcripts involved in the regulation of gene expression; their role in disease development, to date, remains largely under…
Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Jessica Gordon¹, Kimberly Showalter¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
Abstract Number: 0553 • ACR Convergence 2021
IgG from Systemic Sclerosis Patients Induce a Profibrosing and Serotype-dependent Phenotype in Normal Dermal Fibroblast: A Multi-omics Study
Aurélien Chepy¹, Solange Vivier², Fabrice Bray³, Martin Figeac⁴, Jean-Pascal Meneboo⁴, Camille Ternynck⁵, Lucile Guilbert², Manel Jendoubi², Christian Rolando³, David Launay¹, Sylvain Dubucquoi⁶, Guillemette Marot⁵ and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille, France, ²Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille, France, ³Univ. Lille, CNRS, USR 3290 - MSAP - Miniaturisation pour la Synthèse, l'Analyse et la Protéomique, F-59000 Lille, France, Lille, France, ⁴Université de Lille, Functional Genomics Platform, Lille, France., Lille, France, ⁵ULR 2694 – METRICS : évaluation des technologies de santé et des pratiques médicales, université de Lille, CHU de Lille, 59000 Lille, France, Lille, France, ⁶Univ. Lille, U1286 – INFINITE – Institute for Translational Research in Inflammation, F59000 Lille, France, Lille
Background/Purpose: Antinuclear antibodies are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is much more debated. This study explored the…
Abstract Number: 1847 • ACR Convergence 2021
Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
Elizabeth Volkmann¹, Donald Tashkin², Mei Leng², Grace Kim², Jonathan Goldin² and Michael Roth², ¹Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA
Background/Purpose: Esophageal dysmotility is a common feature of systemic sclerosis (SSc) and aspiration of gastric contents may serve as an inciting and/or exacerbating factor in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].